A global pharmaceutical company acquired a newly approved product with a unique MOA and needed to prove its economic and clinical value to decision makers that were generally satisfied with available, cheaper alternatives. Numerof conducted a thorough assessment to identify new claims and supporting data that could be used to influence purchase decisions.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.